Navigation Links
Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsen's Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
Date:9/7/2009

ed to enter into another alliance with Ipsen. This collaboration is an opportunity to grow our pipeline in oncology, our area of expertise. We believe that Debio 0931 may have applications in the treatment of various types of cancer which will increase the quality of life of many cancer patients."

About the partnership

The collaboration between Ipsen and Debiopharm started in 1983 with regards to LHRH analogues, in particular for the triptorelin analogue Decapeptyl(R) (also known as Pamoreline(R) and Diphereline(R)). In October 2007, their partnership was extended to grant Ipsen access to future sustained-release formulations of Decapeptyl(R) developed by Debiopharm, among which a 6-month sustained release formulation that was filed in Europe in September 2008, for the treatment of locally advanced or metastatic prostate cancer. Decapeptyl(R) 1 and 3-month formulations are currently commercialised in more than 60 countries worldwide, including 25 in Europe and they have generated almost EUR 248million in sales in 2008.

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partne
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
2. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
3. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
4. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
5. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
6. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
7. Japanese Cancer Association and Debiopharm Honour Japanese Research
8. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
9. Debiopharm and EPFL Establish an Oncology Chair
10. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
11. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Calif., Jan. 2, 2012 Renowned biochemist Michael A. ... of The Scripps Research Institute January 1, succeeding Richard ... than two decades. (Photo:  http://photos.prnewswire.com/prnh/20120102/DC28698 ... advance the institute,s mission, creating knowledge in the biosciences ...
... . , Even the costliest oriental carpets have ... tiny mistakes in their fine carpets, because only God has ... industry would like to have them are as yet in ... headed by Dr. Markus Lackinger from the Technische Universitt Mnchen ...
... Americans are resolving to address financial issues or lose weight ... looking to find answers to an important question – who ... was commissioned by Identigene, the largest direct-to-consumer DNA paternity testing ... only paternity test available at the drug store, reveals that ...
Cached Biology Technology:Michael A. Marletta Takes Office as New President of Scripps Research Institute 2The art of molecular carpet-weaving 2Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 2Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 3
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... protein research and an extensive investigation of historical literature, ... elephants is actually an African elephant. In a ... Society , led by Enrico Cappellini and Thomas Gilbert ... represent the species, which is likely the remains of ...
... year the Green Project Awards acknowledges projects that ... sustainability. This year, the awards distinguished with ... project SMARTGALP at the tracks Mobilization Initiative of ... are the result of collaborations with MIT Portugal ...
... LOUIS): The Missouri Botanical Garden was recently awarded a $449,641 ... to test new means of using crowd sourcing and gaming ... Library (BHL). Grant funding begins in December 2013 and ends ... Cornell University and the New York Botanical Garden on the ...
Cached Biology News:Researchers unmask centuries-old elephant imposter 2MIT Portugal is a partner of 2 projects distinguished by the Green Project Awards 2Missouri Botanical Garden aims to improve access to digital texts through online gaming 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mouse Anti-Human MCAF-(MCP-1)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: